Amneal has set out the latest targets in its continuing push to unlock value from complex generics, unveiling a trio of US Food and Drug Administration filings for rivals to ProAir (albuterol) inhalation, Lumigan (bimatoprost) ophthalmic solution and Diprivan (propofol) emulsion.
Citing IQVIA data indicating a total US market value of nearly $2bn for the three products – comprising $814m for...




